Vertex Pharma stock: Third-quarter results arrive November 2 for Vertex Pharma stock

Published on 10/21/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings per share reached USD 4.31 in quarter two. Vertex Pharma stock costs EUR 458.40 on October 21, 2026, up 1.16 percent versus Tradegate.

Earnings date and valuation

Vertex Pharmaceuticals scheduled third-quarter results for November 2, 2026, in its October 7, 2026 release.
Second-quarter diluted earnings per share reached USD 4.31, up 8.00 percent year over year.
Vertex Pharma stock costs EUR 458.40 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST, 1.16 percent above the Tradegate close of October 20, 2026.
The Nasdaq listing carries a P/E ratio of 30.07 and a market capitalization of USD 130.7 billion.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharmaceuticals will report third-quarter 2026 results on November 2, 2026, after the market close, according to its October 7, 2026 release. The company will host its earnings call at 4:30 p.m. ET. Vertex Pharma was trading at EUR 458.40 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST, up 1.16 percent versus the Tradegate close of October 20, 2026 at EUR 453.15.

Second-quarter growth sets the baseline

Vertex reported second-quarter 2026 revenue of USD 3.33 billion, up 12.50 percent from the same quarter a year earlier. Net income reached USD 1.10 billion, an increase of 6.50 percent, while diluted earnings per share rose 8.00 percent to USD 4.31, according to Financial Report Insights.

The earnings mix points to a transition inside the portfolio. Newer products contributed to growth while investment in launches and the pipeline limited the pace of profit expansion relative to revenue.

Stock remains below its yearly high

On Nasdaq, Vertex last traded at USD 515.78 on October 21, 2026 at 10:18 a.m. ET. The stock was 7.94 percent below its 52-week high of USD 560.25 and 27.92 percent above its 52-week low of USD 403.16. Trading volume stood at 267,543 shares at that time.

What does November 2 put on the calendar?

The report will provide the next test of Vertex's raised full-year revenue outlook of USD 13.10 billion to USD 13.20 billion. Management also expects non-cystic-fibrosis revenue of at least USD 500.00 million in 2026, while second-quarter gross margin was 85.60 percent, according to Fortune.

Comparison with peers

Vertex Pharma: up 1.16 percent versus Tradegate, P/E 30.07, market capitalization USD 130.7 billion.

Regeneron Pharmaceuticals: down 0.40 percent on Nasdaq, P/E 19.90, market capitalization USD 82.8 billion.

Amgen: down 0.32 percent on Nasdaq, P/E 27.20, market capitalization USD 236.5 billion.

Valuation meets the next report

The Nasdaq quote gives Vertex a P/E ratio of 30.07 and a market capitalization of USD 130.7 billion. The scheduled November 2 report therefore carries more immediate weight than the older second-quarter numbers, because it will update the revenue path and spending picture.

Vertex Pharma stock was trading at EUR 458.40 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST, 1.16 percent above the Tradegate close of October 20, 2026 at EUR 453.15. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.